We are live on ! Find out more
GRCE

Grace Therapeutics
GRCE

23 hedge funds and large institutions have $15M invested in Grace Therapeutics in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

36% more capital invested

Capital invested by funds: $11M → $15M (+$3.96M)

15% more funds holding

Funds holding: 20 → 23 (+3)

1.17% more ownership

Funds ownership: 26.8% → 27.97% (+1.2%)

Holders
23
Holders Change
+3
Holders Change %
+15%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
6
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Cerity Partners
Cerity Partners
New York
+$1.34M
2
ACM
ADAR1 Capital Management
Texas
+$926K
3
Renaissance Technologies
Renaissance Technologies
New York
+$144K
4
XT
XTX Topco
Cayman Islands
+$96.1K
5
Morgan Stanley
Morgan Stanley
New York
+$75K

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
-$628K
2
MFA
Millington Financial Advisors
Illinois
-$59.7K
3
SWM
SeaCrest Wealth Management
New York
-$42K
4
Citigroup
Citigroup
New York
-$8.19K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$89
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
1
Nantahala Capital Management
Connecticut
$4.08M – – –
ACM
2
AIGH Capital Management
Maryland
$3.15M – – –
ACM
3
ADAR1 Capital Management
Texas
$2.22M +$926K +291,538 +83%
Bank of America
4
Bank of America
North Carolina
$1.71M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$1.48M +$47.3K +14,881 +4%
Cerity Partners
6
Cerity Partners
New York
$1.46M +$1.34M +422,732 New
Renaissance Technologies
7
Renaissance Technologies
New York
$449K +$144K +45,220 +53%
Citadel Advisors
8
Citadel Advisors
Florida
$148K +$47.7K +15,032 +55%
XT
9
XTX Topco
Cayman Islands
$106K +$96.1K +30,261 New
Morgan Stanley
10
Morgan Stanley
New York
$88K +$75K +23,600 +1,277%
GCP
11
GSA Capital Partners
United Kingdom
$48K +$43.7K +13,774 New
SWP
12
Stratos Wealth Partners
Ohio
$38.7K +$35.5K +11,182 New
National Bank of Canada
13
National Bank of Canada
Quebec, Canada
$9.37K – – –
TRCT
14
Tower Research Capital (TRC)
New York
$6.73K +$1.06K +335 +21%
BNP Paribas Financial Markets
15
BNP Paribas Financial Markets
France
$2.08K +$1.91K +600 New
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
$2K -$89 -28 -5%
AWM
17
Activest Wealth Management
Florida
$360 – – –
SS
18
SBI Securities
Japan
$349 – – –
SPIA
19
Steward Partners Investment Advisory
New York
$142 – – –
FHA
20
Flagship Harbor Advisors
Massachusetts
$7 +$6 +2 New
NS
21
NBC Securities
Alabama
$6 – – –
FDCDDQ
22
Federation des caisses Desjardins du Quebec
Quebec, Canada
$3 – – –
SCM
23
Stonepine Capital Management
Oregon
– -$628K -211,010 Closed
MFA
24
Millington Financial Advisors
Illinois
– -$59.7K -20,000 Closed
SWM
25
SeaCrest Wealth Management
New York
– -$42K -14,000 Closed
1
2

GRCE Hedge Fund Activity: Q4 2025 in Review

23 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q4 2025, worth a combined $15M — up 36% from $11M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new GRCE positions and 4 closed out — a net gain of 3 holders — while 6 added to existing stakes and 1 trimmed.

The largest buyer was Cerity Partners, opening a new position worth an estimated $1.34M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $628K sold.

  • 23 institutional investors held Grace Therapeutics (GRCE) as of Q4 2025, up from 20 in Q3 2025.
  • Funds reported $15M of Grace Therapeutics stock for Q4 2025, up 36% quarter-over-quarter.
  • 7 funds opened new Grace Therapeutics positions in Q4 2025 and 4 closed out, a net change of +3 holders.
  • The largest Grace Therapeutics buyer in Q4 2025 was Cerity Partners, an estimated $1.34M added.
  • The largest Grace Therapeutics seller in Q4 2025 was Stonepine Capital Management, an estimated $628K sold.

Based on aggregated 13F filings for Q4 2025.